Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;7(11):616-30.
doi: 10.1038/nrneurol.2011.152.

Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis

Affiliations
Review

Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis

Laura Ferraiuolo et al. Nat Rev Neurol. 2011 Nov.

Abstract

Amyotrophic lateral sclerosis (ALS) is a genetically diverse disease. At least 15 ALS-associated gene loci have so far been identified, and the causative gene is known in approximately 30% of familial ALS cases. Less is known about the factors underlying the sporadic form of the disease. The molecular mechanisms of motor neuron degeneration are best understood in the subtype of disease caused by mutations in superoxide dismutase 1, with a current consensus that motor neuron injury is caused by a complex interplay between multiple pathogenic processes. A key recent finding is that mutated TAR DNA-binding protein 43 is a major constituent of the ubiquitinated protein inclusions in ALS, providing a possible link between the genetic mutation and the cellular pathology. New insights have also indicated the importance of dysregulated glial cell-motor neuron crosstalk, and have highlighted the vulnerability of the distal axonal compartment early in the disease course. In addition, recent studies have suggested that disordered RNA processing is likely to represent a major contributing factor to motor neuron disease. Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS.

PubMed Disclaimer

References

    1. Nat Genet. 2006 Apr;38(4):411-3 - PubMed
    1. Trends Neurosci. 2004 Jan;27(1):17-23 - PubMed
    1. J Neurosci. 2010 Jun 2;30(22):7729-39 - PubMed
    1. Neuron. 2004 Jul 8;43(1):19-30 - PubMed
    1. N Engl J Med. 1992 May 28;326(22):1464-8 - PubMed

Publication types

MeSH terms